Related Experiment Video
Updated: Jun 12, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome
Ilkka Sipilä1, Harri Sintonen, Heikki Hietanen
1Hospital for Children and Adolescents, Paediatrics, University of Helsinki, Helsinki, Finland. ilkka.sipila@fimnet.fi
Aim:
To assess the effects of recombinant human growth hormone (rhGH) treatment in children with Prader-Willi syndrome.
Design:
A 1-year study and an observational follow-up visit 10 years later.
Methods:
In 20 patients with Prader-Willi syndrome (PWS): clinical assessment, laboratory tests, body composition analysis by dual energy X-ray absorptiometry, sleep polygraphy, health-related quality of life assessed by 16D.
Results:
Only two patients had normal growth hormone secretion at baseline. All patients were significantly shorter than their expected heights, but experienced catch-up growth during growth hormone treatment. At follow-up, 13 patients had reached adult heights and were markedly taller than historical controls. The cumulative dose of rhGH over 10 years correlated inversely with the total body fat percentage (p = 0.033). However, patients remained severely obese at 10 years. Sleep polygraphy was abnormal in more than half of the patients. Health-related quality of life of the patients remained substantially below that of normal population.
Conclusion:
Growth hormone markedly improved adult height in subjects with PWS when compared to historical data. The cumulative dose of growth hormone correlated with reduction in body fat; nevertheless, patients remained severely obese.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Nature and Nurture
Signs of Puberty
Cellular Adaptation II: Hypertrophy
Huntington Disease l: Introduction
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...